Tenderwize
Back to tender search

Dodávky léků - REMSIMA II 2026

Revmatologický ústav·Praha, Czech Republic·CZK 56.2M | EUR 2.3M·Deadline Jul 13, 2026 · 19 days left·Open·Supplies
High valueStructured notice only
60/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

30 / 100

Risk factors

All submissions must be in Czech. Non-Czech speakers may face translation costs or errors.

Procurement documents (e.g., detailed specifications, contract terms) were not analyzed. Key requirements may be missin...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • CZK 56.2M estimated value
  • Supplies contract
  • 1 lot
  • Duration 36 MONTH
  • Supply of infliximab (L04AB02) for the Rheumatology Institute
  • Continuous deliveries over 36 months
Show full summary

Open tender for the supply of infliximab (REMSIMA II 2026) to the Rheumatology Institute in Prague, Czech Republic. Single lot, 36-month framework with a total estimated value of 56,164,000 CZK. Award based solely on lowest price. Submission deadline: 13 July 2026.

Risks

All submissions must be in Czech. Non-Czech speakers may face translation costs or errors.

Procurement documents (e.g., detailed specifications, contract terms) were not analyzed. Key requirements may be missin...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Supply of infliximab (ATK code L04AB02)
  • Contract duration: 36 months

Administrative

  • Submission must be in Czech language only

Requirements may be incomplete.

Award Criteria

Lot 1

nejnižší celková nabídková cena včetně marže v Kč bez DPH100%

Buyer

Name

Revmatologický ústav

Location

Praha, CZE

Buyer profile

Open profile

Identifier

00023728

Lots (1)

LOT-0001

Dodávky léků - REMSIMA II 2026

Continuous supply of infliximab (ATC L04AB02) as per the contractual annex. One lot covering all requirements.

SuppliesEU fundedElectronic submission

CZK 56.2M

Estimated value

Location

CZ010, Czech Republic

Duration

36 MONTH

Category

Antineoplastic and immunomodulating agents

Selection criteria

Price

Deadline

Deadline Jul 13, 2026

Procurement Details

Publication date
08 Jun 2026
Notice type
Contract notice — standard
Languages
Czech

Reference metadata

Notice subtype
16
Notice version
1
Legal basis
32014L0024

Reference IDs

Tender ID
392956-2026
Source notice ID
012e39e6-df13-4b61-aa0e-c30a0013f6c0

Documents (1)

Similar tenders